JPH0372605B2 - - Google Patents
Info
- Publication number
- JPH0372605B2 JPH0372605B2 JP57182210A JP18221082A JPH0372605B2 JP H0372605 B2 JPH0372605 B2 JP H0372605B2 JP 57182210 A JP57182210 A JP 57182210A JP 18221082 A JP18221082 A JP 18221082A JP H0372605 B2 JPH0372605 B2 JP H0372605B2
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- breast cancer
- patients
- megestrol acetate
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010006187 Breast cancer Diseases 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 16
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 16
- 229960004296 megestrol acetate Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 9
- 206010027476 Metastases Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 15
- 238000001356 surgical procedure Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 206010038111 Recurrent cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000208011 Digitalis Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 238000011360 adjunctive therapy Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011353 adjuvant radiotherapy Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- -1 megestrol acetate Chemical class 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/719,558 US4370321A (en) | 1976-09-01 | 1976-09-01 | Progestational adjuvant therapy |
| AU89358/82A AU558559B2 (en) | 1976-09-01 | 1982-10-14 | Progestational adjuvant therapy |
| CA000413579A CA1205744A (en) | 1976-09-01 | 1982-10-15 | Progestational adjuvant therapy |
| FR8217377A FR2534476B1 (fr) | 1976-09-01 | 1982-10-18 | Complement prophylactique a base de 17a-acyloxy-6 methylpregna-4,6-diene-3,20-dione |
| JP57182210A JPS5973523A (ja) | 1976-09-01 | 1982-10-19 | 黄体ホルモン含有補助治療剤 |
| BE0/209365A BE894860A (fr) | 1976-09-01 | 1982-10-28 | Therapeutique adjuvante par agent progestatif |
| DE19823240044 DE3240044A1 (de) | 1976-09-01 | 1982-10-28 | Verwendung von 17(alpha)-acyloxy-6-methylpregna-4,6-dien-3,20-dionen zur bekaempfung von brustkrebs |
| GB08231069A GB2129297B (en) | 1976-09-01 | 1982-10-29 | Post-mastectomy treatment dosage units containing megestrol acetate |
| MY8231069A MY8800128A (en) | 1976-09-01 | 1988-12-30 | Preparation of post-masectomy treatment medicant |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/719,558 US4370321A (en) | 1976-09-01 | 1976-09-01 | Progestational adjuvant therapy |
| AU89358/82A AU558559B2 (en) | 1976-09-01 | 1982-10-14 | Progestational adjuvant therapy |
| CA000413579A CA1205744A (en) | 1976-09-01 | 1982-10-15 | Progestational adjuvant therapy |
| FR8217377A FR2534476B1 (fr) | 1976-09-01 | 1982-10-18 | Complement prophylactique a base de 17a-acyloxy-6 methylpregna-4,6-diene-3,20-dione |
| JP57182210A JPS5973523A (ja) | 1976-09-01 | 1982-10-19 | 黄体ホルモン含有補助治療剤 |
| BE0/209365A BE894860A (fr) | 1976-09-01 | 1982-10-28 | Therapeutique adjuvante par agent progestatif |
| DE19823240044 DE3240044A1 (de) | 1976-09-01 | 1982-10-28 | Verwendung von 17(alpha)-acyloxy-6-methylpregna-4,6-dien-3,20-dionen zur bekaempfung von brustkrebs |
| GB08231069A GB2129297B (en) | 1976-09-01 | 1982-10-29 | Post-mastectomy treatment dosage units containing megestrol acetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5973523A JPS5973523A (ja) | 1984-04-25 |
| JPH0372605B2 true JPH0372605B2 (enExample) | 1991-11-19 |
Family
ID=36764617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57182210A Granted JPS5973523A (ja) | 1976-09-01 | 1982-10-19 | 黄体ホルモン含有補助治療剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4370321A (enExample) |
| JP (1) | JPS5973523A (enExample) |
| AU (1) | AU558559B2 (enExample) |
| BE (1) | BE894860A (enExample) |
| CA (1) | CA1205744A (enExample) |
| DE (1) | DE3240044A1 (enExample) |
| FR (1) | FR2534476B1 (enExample) |
| GB (1) | GB2129297B (enExample) |
| MY (1) | MY8800128A (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338732A (en) * | 1991-06-18 | 1994-08-16 | Bristol-Myers Squibb Company | Megestrol acetate formulation |
| US6268356B1 (en) | 1998-04-20 | 2001-07-31 | Pharmaceutical Resources, Inc. | Flocculated suspension of megestrol acetate |
| US6028065A (en) * | 1998-04-20 | 2000-02-22 | Pharmaceutical Resources, Inc. | Flocculated suspension of megestrol acetate |
| US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
| SI1669074T1 (sl) * | 2004-12-01 | 2010-10-29 | Par Pharmaceuticals Inc | Uporaba megestrol acetata za izboljšanje delovanja srca in zdravljenje srčnega popuščanja |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB870286A (en) * | 1958-11-04 | 1961-06-14 | British Drug Houses Ltd | Improvements in or relating to 6-methyl-3-oxo-í~-steroid compounds |
| US3453297A (en) * | 1968-07-24 | 1969-07-01 | Merck & Co Inc | 17alpha-lower alkoxy-pregna-4,6-diene-3,20-dione steroids |
| US3591689A (en) * | 1969-06-04 | 1971-07-06 | Mead Johnson & Co | Progestational composition in oral dosage form |
| ZA716118B (en) * | 1970-10-05 | 1972-05-31 | Richardson Merrell Inc | Contraception |
| GB1558472A (en) * | 1976-01-22 | 1980-01-03 | Leo Ab | 17-esters of 17- hydroxy gestogens |
-
1976
- 1976-09-01 US US05/719,558 patent/US4370321A/en not_active Expired - Lifetime
-
1982
- 1982-10-14 AU AU89358/82A patent/AU558559B2/en not_active Expired
- 1982-10-15 CA CA000413579A patent/CA1205744A/en not_active Expired
- 1982-10-18 FR FR8217377A patent/FR2534476B1/fr not_active Expired
- 1982-10-19 JP JP57182210A patent/JPS5973523A/ja active Granted
- 1982-10-28 BE BE0/209365A patent/BE894860A/fr unknown
- 1982-10-28 DE DE19823240044 patent/DE3240044A1/de not_active Ceased
- 1982-10-29 GB GB08231069A patent/GB2129297B/en not_active Expired
-
1988
- 1988-12-30 MY MY8231069A patent/MY8800128A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2534476B1 (fr) | 1987-07-31 |
| CA1205744A (en) | 1986-06-10 |
| JPS5973523A (ja) | 1984-04-25 |
| AU8935882A (en) | 1984-04-19 |
| DE3240044A1 (de) | 1984-05-03 |
| US4370321A (en) | 1983-01-25 |
| FR2534476A1 (fr) | 1984-04-20 |
| BE894860A (fr) | 1983-04-28 |
| GB2129297B (en) | 1986-05-29 |
| AU558559B2 (en) | 1987-02-05 |
| GB2129297A (en) | 1984-05-16 |
| MY8800128A (en) | 1988-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2270003C2 (ru) | Лекарственное средство для лечения солидных опухолей на основе паклитаксела, стабилизированного альбумином | |
| JP2001515032A (ja) | 前立腺がんを治療するためのチロシンキナーゼ阻害剤と化学的去勢術の組み合わせ法 | |
| Ariel | Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors | |
| Geisler | The use of megestrol acetate in the treatment of advanced malignant lesions of the endometrium | |
| Ansfield et al. | Further clinical studies with megestrol acetate in advanced breast cancer | |
| van Dellen, JR & Danziger | Failure of computerized tomography to differentiate between radiation necrosis and cerebral tumour | |
| US4370321A (en) | Progestational adjuvant therapy | |
| Ilias et al. | Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane | |
| Geisler | The use of high-dose megestrol acetate in the treatment of ovarian adenocarcinoma | |
| Thomsen et al. | Extracutaneous spreading with fatal outcome of mycosis fungoides in a patient treated with ciclosporin A: a word of caution | |
| Scarpa et al. | Visceral neoplasia presenting at the umbilicus | |
| KR20010075074A (ko) | 간 종양을 치료하기 위한 메톡시모르폴리노 독소루비신의용도 | |
| Magarey | The control of cancer spread by the reticuloendothelial system | |
| LOWE et al. | Antitumor efficacy of fluoxymesterone: use in advanced breast cancer | |
| IE54348B1 (en) | Preparation of post-mastectomy treatment medicant | |
| Koike et al. | Efficacy of vinblastine and methotrexate in a childhood patient with progressive desmoid fibromatosis of the lower jaw: A case report | |
| Pang et al. | Alveolar soft-part sarcoma: a hormone-sensitive tumour? | |
| Steinbaum et al. | Clinical trial of nafoxidine in advanced breast cancer | |
| Kim et al. | Wells' syndrome following Oxford–AstraZeneca COVID‐19 vaccination. | |
| US20080020030A1 (en) | Use Of 7-T-Butoxyiminomethylcamptothecin For The Preparation Of A Medicament For The Treatment Of Uterine Neoplasms | |
| JP2999539B2 (ja) | 白血球減少症の予防・治療剤 | |
| Bryson et al. | Primary vulvar malignant melanoma: Review and evaluation of surgical management | |
| Brand et al. | Monoclonal antibody imaging of ovarian cancer with intraperitoneal 111In-CYT-103 antibody to TAG-72 antigen | |
| HISAMATSU | Mammary tumorigenesis by subcutaneous administration of a mixture of megestrol acetate and ethynylestradiol in Wistar rats | |
| Goldenberg | Radiopotentiating Action of 1-β-D-Arabinofuranosylcytosine in a |